Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
Holding BVS?
Track your performance easily
BVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.36 - $14.38
Previous Close$11.82
Volume444.62K
Average Volume (3M)597.48K
Market Cap
$912.18M
Enterprise Value$1.29B
Total Cash (Recent Filing)$43.07M
Total Debt (Recent Filing)$383.59M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Mar 20, 2025EPS Estimate
$0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding81,154,567
10 Day Avg. Volume636,085
30 Day Avg. Volume597,481
Standard Deviation0.35
R-Squared0.01
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)6.46
Price to Sales (P/S)1.64
Price to Cash Flow (P/CF)22.10
P/FCF Ratio21.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit3.93
Enterprise Value/Ebitda463.48
Forecast
1Y Price Target
$14.67Price Target Upside24.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bioventus News
PremiumCompany Announcements
Bioventus Reports Strong Revenue Growth in Q3 2024Bulls Say, Bears Say
Bulls Say
Financial PerformanceBVS posted a strong Q3, beating revenue, adjusted EBITDA, and pro forma EPS expectations.
Growth And ExpansionBVS raised FY24 expectations for growth in the segment due to strong volume gains and HA reimbursement headwinds being resolved.
Strategic DivestitureThe sale of the Advanced Rehabilitation business will allow BVS to continue its journey of streamlining its focus and strategy on its highest impact segments.
Bears Say
Business GrowthBVS expects some weaker growth in its BGS business as it works to onboard new distributors.
EBITDA ImpactBVS will lose around 6% of its trailing twelve months adjusted EBITDA as a result of the divestiture.
Revenue ImpactBVS will lose approximately 9% of its trailing twelve months revenues due to the divestiture.
---
Ownership Overview
31.98% Insiders
5.33% Mutual Funds
2.97% Other Institutional Investors
52.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BVS FAQ
What was Bioventus’s price range in the past 12 months?
Bioventus lowest stock price was $3.36 and its highest was $14.38 in the past 12 months.
What is Bioventus’s market cap?
Currently, no data Available
When is Bioventus’s upcoming earnings report date?
Bioventus’s upcoming earnings report date is Mar 20, 2025 which is in 130 days.
How were Bioventus’s earnings last quarter?
Bioventus released its earnings results on Nov 05, 2024. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.016 by $0.044.
Is Bioventus overvalued?
According to Wall Street analysts Bioventus’s price is currently Undervalued.
Does Bioventus pay dividends?
Bioventus does not currently pay dividends.
What is Bioventus’s EPS estimate?
Bioventus’s EPS estimate is $0.08.
How many shares outstanding does Bioventus have?
Bioventus has 65,367,830 shares outstanding.
What happened to Bioventus’s price movement after its last earnings report?
Bioventus reported an EPS of $0.06 in its last earnings report, beating expectations of $0.016. Following the earnings report the stock price went down -16.265%.
Which hedge fund is a major shareholder of Bioventus?
Among the largest hedge funds holding Bioventus’s share is EntryPoint Capital, LLC. It holds Bioventus’s shares valued at N/A.
---
Bioventus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.67 (24.11% Upside)
$14.67 (24.11% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 9.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $901.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.9%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
210.23%
12-Months-Change
Fundamentals
Return on Equity
-24.20%
Trailing 12-Months
Asset Growth
-5.13%
Trailing 12-Months
Company Description
Bioventus
Bioventus Inc is a medical technology company incorporated in Delaware on December 22, 2015. The Company is engaged in developing and commercializing orthobiologic products for the treatment of patients suffering from a broad array of musculoskeletal conditions. Its products address the growing need for clinically effective, cost efficient and minimally invasive solutions that enhance the body's natural healing processes. The Company operates through four segments including Active Healing Therapies-U.S., Active Healing Therapies-International, Surgical and BMP. The Company's Active Healing Therapies segments offer two types of non-surgical products including non-invasive Exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief.
---
BVS Company Deck
---
BVS Earnings Call
Q3 2024
0:00 / 0:00
---
BVS Stock 12 Month Forecast
Average Price Target
$14.67
▲(24.11% Upside)
Technical Analysis
Best Analysts Covering BVS
1 Year
1 Year Success Rate
9/9 ratings generated profit
1 Year Average Return
+82.81%
reiterated a buy rating 4 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +82.81% per trade.
---